CTLT: Catalent, Inc. Stock

by  •  • Comments Off on CTLT: Catalent, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 10,709.18
Enterprise Value ($M) 14,949.18
Book Value ($M) 3,542.00
Book Value / Share 19.51
Price / Book 3.02
NCAV ($M) -3,659.00
NCAV / Share -20.16
Price / NCAV -2.93

Profitability (mra)
Return on Invested Capital (ROIC) -0.05
Return on Assets (ROA) -0.04
Return on Equity (ROE) -0.11

Liquidity (mrq)
Quick Ratio 1.96
Current Ratio 2.51

Balance Sheet (mrq) ($M)
Current Assets 2,507.00
Assets 9,708.00
Liabilities 6,166.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 4,381.00
Operating Income -62.00
Net Income -1,043.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 268.00
Cash from Investing -327.00
Cash from Financing 74.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
8 days ago 13G/A Janus Henderson Group Plc 0.10 -98.48
8 days ago 13G/A Nomura Holdings Inc 0.60 -89.80
9 days ago 13G/A Capital World Investors 3.50 -33.70
02-14 13G/A T. Rowe Price Investment Management, Inc. 6.20 -32.39
02-13 13G/A Vanguard Group Inc 11.17 3.05
02-12 13G/A Veritas Asset Management LLP 3.58 -42.09
01-25 13G/A BlackRock, Inc. 9.00 17.31

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 20
2024-10-25 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2024 or ☐ TRANSITION REPOR
2024-09-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTIO
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o
2024-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 202
2023-12-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTIO
2023-12-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 20

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-21 126,402 1,053,518 12.00
2024-11-20 232,497 1,251,321 18.58
2024-11-19 79,525 618,467 12.86
2024-11-18 127,866 1,143,468 11.18

(click for more detail)

Similar Companies
BHC – Bausch Health Companies Inc. BHVN – Biohaven Ltd.
BMY – Bristol-Myers Squibb Company EBS – Emergent BioSolutions Inc.
ELAN – Elanco Animal Health Incorporated


Financial data and stock pages provided by
Fintel.io